Clinical Oncology
Volume 18, Issue 4 , Pages 345-350 , May 2006

Symptomatic Responses to Neoadjuvant Chemotherapy for Carcinoma of the Oesophagus and Oesophagogastric Junction: Are They Worth Measuring?

  • M.J. Forshaw

      Affiliations

    • Department of General Surgery, UK
    • ,
  • J.A. Gossage

      Affiliations

    • Department of General Surgery, UK
    • ,
  • K. Chrystal

      Affiliations

    • Department of Medical Oncology, Guy's and St Thomas' NHS Trust, St Thomas' Hospital, London, UK
    • ,
  • K. Cheong

      Affiliations

    • Department of Medical Oncology, Guy's and St Thomas' NHS Trust, St Thomas' Hospital, London, UK
    • ,
  • P.G. Harper

      Affiliations

    • Department of Medical Oncology, Guy's and St Thomas' NHS Trust, St Thomas' Hospital, London, UK
    • ,
  • R.C. Mason

      Affiliations

    • Department of General Surgery, UK
    • Corresponding Author InformationAuthor for correspondence: Robert Mason, Department of General Surgery, Guy's and St Thomas' NHS Trust, St Thomas' Hospital, Lambeth Palace Road, London SE1 7EH, UK. Tel: +44-207-188-2563; Fax: +44-207-188-0883.

Received 2 July 2005 ,Revised 2 February 2006 ,Accepted 14 February 2006.

References 

  1. Pera M, Cameron AJ, Trastek VF, et al. Increasing incidence of adenocarcinoma of the esophagus and esophagogastric junction. Gastroenterology. 1993;104:510–513
  2. Siewert JD, Stein HJ. Classification of adenocarcinoma of the oesophagogastric junction. Br J Surg. 1998;85:1457–1459
  3. Hofstetter W, Swisher SG, Correa AM, et al. Treatment outcomes of resected esophageal cancer. Ann Surg. 2002;236:376–385
  4. DeCamp MM, Swanson SJ, Jaklitsch MT. Esophagectomy after induction chemoradiation. Chest. 1999;116:466S–469S
  5. Harrison LE, et al. Is esophageal cancer a surgical disease?. J Surg Oncol. 2000;75:227–231
  6. Walsh TN, Grennell M, Mansoor S, et al. Neoadjuvant treatment of advanced stage esophageal adenocarcinoma increases survival. Dis Esophagus. 2002;15:121–124
  7. Jonker D, Mehran R, Maroun J, et al. Neoadjuvant chemotherapy before surgery for resectable carcinoma of the lower esophagus. Dis Esophagus. 1999;12:144–148
  8. Walsh TN, Noonan N, Hollywood D, et al. A comparison of multimodal therapy and surgery for esophageal adenocarcinoma. N Engl J Med. 1996;335:462–467
  9. Archer VR, Mulholland PJ, Stocken DD, Darnton SJ, Ferry DR. Combined results from three phase II trials of neoadjuvant chemotherapy in operable adenocarcinoma of the oesophagus. Clin Oncol. 2001;13:164–169
  10. Kelsen DP, Ginsberg R, Pajak TF, et al. Chemotherapy followed by surgery compared with surgery alone for localised esophageal cancer. N Engl J Med. 1998;339:1979–1984
  11. Law S, Fok M, Chow S, et al. Preoperative chemotherapy versus surgical therapy alone for squamous cell carcinoma of the esophagus: a prospective randomised trial. J Thorac Cardiovasc Surg. 1997;114:210–217
  12. Ancona E, Ruol A, Santi S, et al. Only pathologic complete response to neoadjuvant chemotherapy improves significantly the long term survival of patients with respectable esophageal squamous cell carcinoma. Cancer. 2001;91:2165–2174
  13. Roth JA, Pass HI, Flanagan MM, et al. Randomised clinical trial of preoperative and postoperative adjuvant chemotherapy with cisplatin, vindesine and bleomycin for carcinoma of the esophagus. J Thorac Cardiovasc Surg. 1988;96:242–248
  14. Brown WA, Thomas J, Gotley D, et al. Use of oesophagogastroscopy to assess the response of oesophageal carcinoma to neoadjuvant therapy. Br J Surg. 2004;91:199–2004
  15. Giovannini M, Seitz JF, Thomas P, et al. Endoscopic ultrasonography for assessment of the response to combined radiation and chemotherapy in patients with esophageal cancer. Endoscopy. 1997;29:4–9
  16. Steyn RS, Grenier I, Darnton SJ, et al. Weight gain as an indicator of response to chemotherapy for oesophageal carcinoma. Clin Oncol. 1995;7:382–384
  17. World Health Organisation . WHO handbook for reporting results of cancer treatment. Geneva: WHO; 1979;(publication no. 48)
  18. Medical Research Council Oesophageal Cancer Working Party . Surgical resection with or without neoadjuvant chemotherapy in oesophageal cancer: a randomised control trial. Lancet. 2002;359:1727–1733
  19. Mandard A, Dalibard F, Mandard JC, et al. Pathological assessment of tumour regression after preoperative chemoradiotherapy of esophageal carcinoma: clinicopathological correlations. Cancer. 1994;88:2680–2686
  20. Andreyev HJN, Norman AR, Cunningham D, et al. Squamous oesophageal cancer can be downstaged using protracted venous infusion of 5-fluorouracil with epirubicin and cisplatin (ECF). Eur J Cancer. 1995;31A:2209–2214
  21. Bamias A, Hill ME, Cunningham D, et al. Epirubicin, cisplatin and protracted venous infusion of 5-fluorouracil for esophagogastric adenocarcinoma. Cancer. 1996;77:1978–1985
  22. Geh JI, Glynne-Jones R, Kwok QSK, et al. Preoperative ECF chemotherapy in gastro-oesophageal adenocarcinoma. Clin Oncol. 2000;12:182–187
  23. Doig L, Meenan J, Vu C. Large series prospective experience with EUS for post chemotherapy staging of oesophageal cancer. Time to answer the question of clinical value. Gut. 2004;54(Suppl II):A57
  24. Andreyev HJN, Norman AR, Oates J, et al. Why do patients with weight loss have a worse outcome when undergoing chemotherapy for gastrointestinal malignancies. Eur J Cancer. 1998;34:503–509
  25. McCulloch P, Ward J, Tekkis PP. Mortality and morbidity in gastro-oesophageal cancer surgery: initial results of ASCOT multicentre prospective cohort study. BMJ. 2003;327:1192–1198
  26. Bailey SH, Bull DA, Harpole DH, et al. Outcomes after esophagectomy: a ten-year prospective cohort. Ann Thorac Surg. 2003;75:217–222
  27. Blazeby JM, Farndon JR, Donovan J, et al. A prospective longitudinal study examining the quality of life of patients with esophageal carcinoma. Cancer. 2000;88:1781–1787
  28. Jones Report . A positive approach to nutrition as treatment. London: Kings Funds Centre; 1992;
  29. Urschel JD, Vasan H, Blewett CJ. A meta-analysis of randomized controlled trials that compared neoadjuvant chemotherapy and surgery to surgery alone for resectable esophageal cancer. Am J Surg. 2002;183:274–279
  30. Lordick F, Stein HJ, Peschel C, et al. Neoadjuvant therapy for oesophagogastric cancer. Br J Surg. 2004;91:540–551
  31. Bates BA, Detterbeck FC, Bernard SA, et al. Concurrent radiation therapy and chemotherapy followed by esophagectomy for localised esophageal carcinoma. J Clin Oncol. 1996;14:156–163
  32. van Raemdonck D, Van Cutsem E, Menten J, et al. Induction therapy for clinical T4 oesophageal carcinoma; a plea for continued surgical exploration. Eur J Cardiothorac Surg. 1997;11:828–837
  33. Mariette C, Finzi L, Fabre S, et al. Factors predictive of complete resection of operable esophageal cancer: a prospective study. Ann Thorac Surg. 2003;75:1720–1726
  34. Walsh TN, Grannell M, Mansoor S. Predictive factors for success of neoadjuvant therapy in upper gastro-intestinal cancer. J Gastroenterol Hepatol. 2002;17:S172–S175
  35. Kostakoglu L, Goldsmith SJ. PET in the assessment of therapy response in patients with carcinoma of the head and neck and of the esophagus. J Nucl Med. 2004;45:56–68

PII: S0936-6555(06)00052-5

doi: 10.1016/j.clon.2006.02.008

Clinical Oncology
Volume 18, Issue 4 , Pages 345-350 , May 2006

Article Tools

* Image Usage & Resolution